Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05009862 · ClinicalTrials.gov registry record · Phase 4
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
A Phase 4 study of Peripheral Arterial Disease, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT05009862 is a Phase 4 study of Peripheral Arterial Disease that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 75 participants, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05009862, a Phase 4 study of Peripheral Arterial Disease, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aspirin 81Mg Ec Tab
- DRUG Rivaroxaban 2.5 Mg Oral Tablet
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05009862
The ClinicalTrials.gov registry entry for NCT05009862 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,205-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (98% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05009862 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05009862 about?
NCT05009862 is a clinical study titled "The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease". The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
What is the current status of trial NCT05009862?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2022-04-19. Estimated completion is 2026-03-01.
What conditions does trial NCT05009862 study?
This clinical trial studies the following conditions: Peripheral Arterial Disease.
What interventions are being tested in trial NCT05009862?
The interventions under investigation include: Placebo (DRUG), Aspirin 81Mg Ec Tab (DRUG), Rivaroxaban 2.5 Mg Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT05009862?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05009862 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
RECRUITING · Phase 4
-
Vascular Trial Associated Registry Pilot
RECRUITING · Phase 4
-
The Jetstream G3™ Calcium Study
COMPLETED · Phase 4
-
SELUTION4BTK Trial
RECRUITING · NA
-
MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology
RECRUITING · NA
-
A Real-World Registry of Chronic Wounds and Ulcers
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.